De Philippis C, Zucchinetti C, Mannina D, Krampera M, et al. Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma. Bone Marrow Transplant 2024 Jan 25. doi: 10.1038/s41409-024-02205.
PMID: 38272998